With Only Grant Revenue Trickling In, Helicos' R&D Costs Deepen Q3 Loss

Nov 01, 2007

NEW YORK (GenomeWeb News) — In its second quarterly earnings report since its initial public offering in May, Helicos today said it gained minimal revenue from grants while R&D spending rose 73 percent and its net loss grew by 68 percent compared to the prior-year period.

Total receipts for its third quarter ended Sept. 30 were $230,000 while the company claimed no revenue for the third quarter of 2006.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

More to Do

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

This Week in PLOS

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

'Follow Me to Maryland'

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Main menu